Short-Course TB Treatment: Landmark Trial Results Published in Peer-Reviewed Journal

NIH/NIAID Template Banner

Wednesday, May 5, 2021

Short-Course TB Treatment: Landmark Trial Results Published in Peer-Reviewed Journal

Scanning electron micrograph of Mycobacterium tuberculosis, the bacterium that causes TB

A large international clinical trial has established that a new four-month daily treatment regimen is as safe and effective as the standard six-month daily regimen at curing drug-susceptible tuberculosis disease, researchers report today in the New England Journal of MedicineResults from the Phase 3 trial, led by the CDC's Tuberculosis Trials Consortium and supported in part by the NIAID-funded AIDS Clinical Trials Group, were first presented in October 2020 at the Union World Conference on Lung Health. A shorter regimen has the potential to increase completion of therapy, improve patient quality of life, reduce treatment costs, and decrease development of drug resistance. 

Read More


This email was sent to rssproject471@gmail.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107 GovDelivery logo

Postingan terkait:

Belum ada tanggapan untuk "Short-Course TB Treatment: Landmark Trial Results Published in Peer-Reviewed Journal"

Post a Comment